U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8801161

Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage.

CNS Activity

Curator's Comment: Evidence indicates that retinol is transported by retinol binding protein across the blood–brain barrier and blood–CSF barrier to the CNS

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O95237
Gene ID: 9227.0
Gene Symbol: LRAT
Target Organism: Homo sapiens (Human)
Target ID: Q96NR8
Gene ID: 145226.0
Gene Symbol: RDH12
Target Organism: Homo sapiens (Human)
Target ID: Q92781
Gene ID: 5959.0
Gene Symbol: RDH5
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
AQUASOL A

Approved Use

Used to treat and prevent symptoms of vitamin A deficiency such as xerophthalmia and night blindness. Used as a dietary supplement to prevent vitamin A deficiency in patients with GI diseases (e.g., malabsorption syndromes) and those with abnormal storage and transport of vitamin A (e.g., abetalipoproteinemia, protein deficiency, diabetes mellitus, hyperthyroidism, fever, liver disease, cystic fibrosis with hepatic involvement).

Launch Date

1949
Palliative
AQUASOL A

Approved Use

Children with severe measles have been found to have low serum concentrations of vitamin A; WHO and AAP recommend that vitamin A supplements be given to all children with acute measles, regardless of their country of residence.

Launch Date

1949
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption.
2006-03
Retinoic acid regulates sex-specific timing of meiotic initiation in mice.
2006-02-21
RPE65 is an iron(II)-dependent isomerohydrolase in the retinoid visual cycle.
2006-02-03
Vitamin A improves Pax3 expression that is decreased in the heart of rats with experimental diaphragmatic hernia.
2006-02
The acute and chronic toxic effects of vitamin A.
2006-02
Comparative ligand-binding analysis of ten human lipocalins.
2006-02
Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells.
2006-02
Role of retinoic acid receptors alpha1 and gamma in the response of murine limbs to retinol in vitro.
2006-01
Renal pathology and retinol status in multiple myeloma patients.
2006-01
Expression of Connexin 43 in the hearts of rat embryos exposed to nitrofen and effects of vitamin A on it.
2006-01
Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis.
2006-01
Effects of nitrofen and vitamins A, C and E on maturation of cultured human H441 pneumocytes.
2006
The effect of vitamin A on CCl4-induced hepatic injuries in rats: a histochemical, immunohistochemical and ultrastructural study.
2006
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle.
2005-12-15
Vitamin A status in mice affects the histone code of the phosphoenolpyruvate carboxykinase gene in liver.
2005-12
Retinoid metabolism during development of liver cirrhosis.
2005-11-15
Retinol inhibits the growth of all-trans-retinoic acid-sensitive and all-trans-retinoic acid-resistant colon cancer cells through a retinoic acid receptor-independent mechanism.
2005-11-01
Development of a versatile reporter assay for studies of retinol uptake and metabolism in vivo.
2005-11-01
Megalin-mediated reuptake of retinol in the kidneys of mice is essential for vitamin A homeostasis.
2005-11
Expression of nuclear receptor and target genes in liver and intestine of neonatal calves fed colostrum and vitamin A.
2005-11
Retinol induces permeability transition and cytochrome c release from rat liver mitochondria.
2005-10-30
Acyl coenzyme A dependent retinol esterification by acyl coenzyme A: diacylglycerol acyltransferase 1.
2005-10-15
Vitamin A regulation of BMP4 expression in the male germ line.
2005-10-01
Vitamin A supplementation induces adipose tissue loss through apoptosis in lean but not in obese rats of the WNIN/Ob strain.
2005-10
Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
2005-10
Comparison of indices of vitamin A status in children with chronic liver disease.
2005-10
Transmembrane protein GDE2 induces motor neuron differentiation in vivo.
2005-09-30
Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.
2005-09-20
Hypervitaminosis A resulting in DNA aberration in fetal transgenic mice (Muta Mouse).
2005-09-05
Expression of keratinocyte transglutaminase in cornea of vitamin A-deficient rats.
2005-09
beta-cryptoxanthin stimulates cell differentiation and mineralization in osteoblastic MC3T3-E1 cells.
2005-08-15
Fortification of maize meal improved the nutritional status of 1-3-year-old African children.
2005-08
Effects of prenatal vitamins A, E, and C on the hypoplastic hearts of fetal rats with diaphragmatic hernia.
2005-08
Phospho-STAT5 accumulation in nuclear fractions from vitamin A-deficient rat liver.
2005-07-04
Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension.
2005-06-14
Effect of vitamin A content in cafeteria diet on the expression of nuclear receptors in rat subcutaneous adipose tissue.
2005-06
Vitamin a deficiency and anaemia in young children living in a malaria endemic district of western Kenya.
2005-06
Vitamin A deficiency induces prooxidant environment and inflammation in rat aorta.
2005-06
Inhibitory effects of vitamin A on TCDD-induced cytochrome P-450 1A1 enzyme activity and expression.
2005-05
Alcohol, vitamin A, and cancer.
2005-04
Brain tissue fragments in the amniotic fluid of rats with neural tube defect.
2005-04
What is the safe dose of vitamin A in children with measles?
2005-04
Retinoid receptor mRNA expression profiles in human bladder cancer specimens.
2005-04
Extra-hepatic vitamin A concentrations in captive Rhesus (Macaca mulatta) and Marmoset (Callithrix jacchus) monkeys fed excess vitamin A.
2005-03
Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months.
2005-03
Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on vitamin A metabolism in mice.
2005
Protein and m-RNA expression of farnesyl-transferases, RhoA and RhoB in rat liver hepatocytes: action of perillyl alcohol and vitamin A in vivo.
2005
Differential effects of vitamin A on fetal lung growth and diaphragmatic formation in nitrofen-induced rat model.
2005
Age differences in vitamin A intake among Canadian Inuit.
2004-12-30
Use of the deuterated-retinol-dilution technique to monitor the vitamin A status of Nicaraguan schoolchildren 1 y after initiation of the Nicaraguan national program of sugar fortification with vitamin A.
2004-11
Patents

Sample Use Guides

Weekly single oral dose 7000 micrograms
Route of Administration: Oral
The role of vitamin A (2.72 μM/7 ml culture), a naturally occurring antioxidant upon arsenic-induced genotoxicity; with respect to chromosomal aberrations (structural and numerical) and micronuclei. Whole blood cultures set for 72 h were exposed to test chemicals for a period of 24 h ahead of harvesting. Arsenic concentrations tested in the present study are 0.36, 0.72 and 1.4 μM/7 ml culture. Mitomycin C (MMC), the direct acting mutagen was used as positive control.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:25:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:25:13 GMT 2025
Record UNII
81G40H8B0T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHOCOLA A
Preferred Name English
VITAMIN A
FCC   GREEN BOOK   MART.   ORANGE BOOK   USP   VANDF  
Common Name English
LUTAVIT A
Common Name English
VITAMIN A [VANDF]
Common Name English
VITAMIN A [EP MONOGRAPH]
Common Name English
VITAMIN A (NATURAL) [VANDF]
Common Name English
PROVITAMIN A
Common Name English
VITAMIN A, UNSPECIFIED FORM
Common Name English
VITAMIN A [ORANGE BOOK]
Common Name English
VIATMIN A [VANDF]
Common Name English
VITAMIN A CONCENTRATE [WHO-IP]
Common Name English
VITAMIN A [FCC]
Common Name English
VITAMIN A [GREEN BOOK]
Common Name English
HYDROVIT A
Common Name English
ROVIMIX A 500
Common Name English
VITAMIN A [USP MONOGRAPH]
Common Name English
MICROVIT A
Common Name English
VITAMIN A [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000006269
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
CFR 21 CFR 862.1805
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
NDF-RT N0000006269
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
WHO-ATC V04CB01
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
DSLD 3315 (Number of products:1063)
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
NDF-RT N0000006269
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
NDF-RT N0000006269
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
NDF-RT N0000006269
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
CFR 21 CFR 101.78
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
FDA ORPHAN DRUG 546216
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
CFR 21 CFR 184.1930
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
WHO-VATC QV04CB01
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
DSLD 2698 (Number of products:2377)
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
LIVERTOX NBK548165
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
NDF-RT N0000175950
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
DSLD 201 (Number of products:4964)
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
234-328-2
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID301014459
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
DRUG BANK
DB00162
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
EVMPD
SUB16102MIG
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
LACTMED
Vitamin A
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL986
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
DAILYMED
81G40H8B0T
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
CAS
11103-57-4
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
CHEBI
17616
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
RXCUI
11246
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
VITAMIN A
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
EVMPD
SUB05791MIG
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
NCI_THESAURUS
C938
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
MESH
D014801
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
FDA UNII
81G40H8B0T
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
CHEBI
17336
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
VITAMIN A
Created by admin on Mon Mar 31 18:25:13 GMT 2025 , Edited by admin on Mon Mar 31 18:25:13 GMT 2025
PRIMARY Description: A yellow to brownish yellow, oily liquid.Solubility: Practically insoluble in water; soluble or partly soluble in dehydrated ethanol R; miscible with organic solvents.Category: Vitamin.Storage: The oily form of Retinol concentrate should be kept in a well-closed and well-filled container, protected from light. Oncethe container has been opened its contents should be used as soon as possible; any part of the contents not used at once shouldbe protected by an atmosphere of inert gas.Labelling: The designation on the container should state the name of the retinol ester or esters, and their quantities expressed asthe content of vitamin A in International Units (IU) per gram, whether any stabilizing agents are added and their quantities, as wellas the method of restoring the solution if partial crystallization has occurred.Additional information: Even in the absence of light the oily form of Retinol concentrate is gradually degraded on exposure to ahumid atmosphere, the decomposition being faster at higher temperatures.Partial crystallization may occur in concentrated solutions and upon refrigeration.
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
DERIVATIVE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
ACTIVE MOIETY
Definition References